BerGenBio ASA CEO Martin Olin Steps Down

BerGenBio ASA (BRRGF) has released an update.

BerGenBio ASA announces the departure of CEO Martin Olin, who has led the company through strategic transitions and the development of its lead drug candidate, bemcentinib. The Board of Directors is now initiating a search for a new CEO to continue advancing the company’s pipeline. BerGenBio, a biopharmaceutical company focused on developing AXL inhibitors for severe diseases, remains poised for an exciting future as Olin commits to following its progress.

For further insights into BRRGF stock, check out TipRanks’ Stock Analysis page.